MIT Technology Review Narrated This company is developing gene therapies for muscle growth, erectile dysfunction, and “radical longevity”
11 snips
Apr 15, 2026 A company plans clinical tests of gene therapies aimed at boosting blood flow and stimulating muscle growth. The conversation covers different delivery methods like plasmids versus AAV and the safety tradeoffs. Listeners hear about clinics and influencers offering unproven treatments abroad. Ethical questions arise about giving risky enhancements to healthy people.
AI Snips
Chapters
Transcript
Episode notes
Small Volunteer Trial Targets Radical Life Extension
- Unlimited Bio plans to give healthy volunteers two gene therapies aiming to boost muscle blood supply and growth as a step toward radical life extension.
- The trial enrolls 12–15 self-funded volunteers who will get multiple intramuscular injections and won't provide definitive longevity evidence.
Prospera Clinic Sells Folistatin To Wealthy Clients
- MiniCircle has been offering a folistatin gene therapy in Prospera clinics for a reported $25,000 and attracted wealthy influencers like Brian Johnson.
- Prospera's special regulatory zone enables clinics to deliver unapproved enhancement therapies to anyone who pays.
Company Uses Prospera To Advance VEGF And Follistatin Trials
- Unlimited Bio incorporated in Prospera and is developing VEGF and follistatin therapies to improve muscle vascularization, repair, and growth.
- They assert treatments won't alter germline DNA and aim for preventative/enhancing indications in healthy people.